Feds Should Own Gilead Hep C Patent, Nonprofit Says
A patent covering Gilead Sciences Inc.'s blockbuster line of sofosbuvir-based hepatitis C drugs doesn't disclose related government funding, meaning the U.S. Department of Health and Human Services has the right to...To view the full article, register now.
Already a subscriber? Click here to view full article